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Why choice of metric matters in public health
analyses: a case study of the attribution of credit
for the decline in coronary heart disease
mortality in the US and other populations
Hebe N Gouda1,2*, Julia Critchley3,4, John Powles1 and Simon Capewell5
Abstract
Background: Reasons for the widespread declines in coronary heart disease (CHD) mortality in high income
countries are controversial. Here we explore how the type of metric chosen for the analyses of these declines
affects the answer obtained.
Methods: The analyses we reviewed were performed using IMPACT, a large Excel based model of the
determinants of temporal change in mortality from CHD. Assessments of the decline in CHD mortality in the USA
between 1980 and 2000 served as the central case study.
Results: Analyses based in the metric of number of deaths prevented attributed about half the decline to
treatments (including preventive medications) and half to favourable shifts in risk factors. However, when mortality
change was expressed in the metric of life-years-gained, the share attributed to risk factor change rose to 65%. This
happened because risk factor changes were modelled as slowing disease progression, such that the hypothetical
deaths averted resulted in longer average remaining lifetimes gained than the deaths averted by better treatments.
This result was robust to a range of plausible assumptions on the relative effect sizes of changes in treatments and
risk factors.
Conclusions: Time-based metrics (such as life years) are generally preferable because they direct attention to the
changes in the natural history of disease that are produced by changes in key health determinants. The life-years
attached to each death averted will also weight deaths in a way that better reflects social preferences.
Keywords: Comparative Effectiveness Research, Policy analysis, Determinants of Mortality, Epidemiologic Methods,
Coronary Heart Disease
Background
Public health policy is powerfully influenced by assump-
tions about past successes. In the last decades of the
20th century, most high income countries experienced
substantial declines in premature deaths from major
vascular diseases. Interpretation of the reasons for these
declines remains relevant to contemporary deliberations
on public health policy.
The coronary heart disease model, IMPACT, which
was first developed by Capewell and colleagues in the
late 1990s has been used to estimate the relative contri-
butions of risk factor changes and clinical treatments to
observed declines in coronary heart disease (CHD) mor-
tality. As initially developed, IMPACT expressed mortal-
ity declines in the metric of ‘deaths prevented or
postponed’ (DPP). Assessments, using DPP, have been
published of the relative contribution of risk factor
changes and better treatment to CHD declines in Scot-
land [1], England and Wales [2], Ireland [3], the USA
[4], Poland (unpublished), New Zealand [5], Finland [6]
China (Beijing) [7] and elsewhere.
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For some of these populations Capewell et al have
extended their analyses by expressing the mortality
decline in the metric of life years gained (LYG): England
and Wales [8], Scotland [9], Ireland [10] and the US
[11]. A comparison of the pairs of results in these 4
countries shows that a much larger share of the credit
was attributed to risk factor changes when analyses were
based in LYG (Figure 1).
Pairs of studies: DPP versus LYG
IMPACT is a very large model implemented in Excel. It
uses data on age and sex specific levels of up to 6 popula-
tion-based risk factors as well as nine specific treatments
for nine disease states, all stratified by age and sex.
Results of four pairs of studies using the IMPACT
model are shown in Figure 1. The studies using DPP
attributed between one half and two thirds of the gains
from 1970 to 2000 to favourable shifts in risk factor
levels. However, the corresponding analyses using LYG
have attributed much more of the gains (up to 79%) to
RF changes.
Despite the sensitivity of results to the choice of
metric, there has been little published discussion of the
respective merits of models based in these alternative
metrics. Here we explore why the results obtained in
these analyses turn out to be so sensitive to the choice
of metric. We also assess the robustness of the
associated assumptions. Our review concentrates mainly
on the decline in the population risks of CHD death in
the USA between 1980 and 2000 [4,11] and addresses
two questions: how do the differences in the attribution
of credit come about? And do the extra assumptions
required for the LYG analyses make them less robust?
In the discussion we reflect on the wider implications of
this case study.
Methods and Results
How does the difference in attributed credit come about?
Within IMPACT, reduced population risks of CHD
death derive from two sources:
1 Better treatment: By definition this only applies to
those patients who come to clinical attention, either
because of the onset of clinical CHD or the detection of
elevated risk factors. Treatment benefits derive either
from reduced case fatality due to clinical management
of an acute or chronic episode of CHD or from the
therapeutic (pharmacological) reduction in elevated
blood pressure or blood cholesterol levels (statin-
induced LDL-C lowering for example). The gains from
preventive treatments (such as statins) are shown dis-
tinct from risk factor improvement gains, (such as fol-
lowing reduction in population levels of cholesterol). To
gain credit for a ‘death prevented or postponed’ an
advance in treatment has to result in survival for at least
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Figure 1 Results of pairs of studies using IMPACT: estimates for percentage contributions of better treatments and favorable risk factor
changes to observed reductions in the risk of death from Coronary Heart Disease comparing the estimated contributions to deaths prevented
or postponed (DPP, top) with those estimating contributions to life years gained (LYG, bottom).
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12 months longer than expected under baseline treat-
ment. For the corresponding analyses using LYG, each
death averted by advances in treatment is assigned an
expected remaining life time (derivation discussed
further below). The sum of these provides the LYG
from treatment advances. When calculating LYG, the
expected remaining lifetime is estimated using mortality
rates observed in those surviving beyond the first thirty
days after the onset of clinical CHD.
2 Risk factor changes: Shifts to more favourable risk
factor levels are modelled to reduce progression through
the natural history (Figure 2). This increases the person
time spent in states with lower risks of fatal CHD -
which, in turn, reduces deaths (countable as DPP as out-
lined above). For each death averted, an expected
remaining lifetime is assigned, based on the stage of the
natural history to which the individual has progressed.
The sum provides the LYG [12-15].
* This is a simplification of the actual model, in which
transitions between a larger range of states are modelled
Key for Figure 2
Weights:
1- General US life expectancy
2- Mid-way between general US life expectancy and
survival rate for post-AMI patient group
3- Equivalent to the survival rate for the post-AMI
patient group
4- Patient group specific survival rates
The overall findings from these analyses are summar-
ized in Figure 1 and Table 1. The last column in Table
1 shows that each death averted by better treatment is
estimated to generate about half as many extra years
lived as is each death averted by favorable shifts in risk
factors.
In Figure 3 the DPP and LYG are plotted against the
age of the averted death. Not surprisingly, when each
death averted is weighted by its LYG, changes in popu-
lation disease experience at earlier ages contribute more
to the aggregated benefit. Deaths averted before age 65
by favourable shifts in risk factors contribute 15.9% of
the total DPPs but 36.2% of total LYGs.
* All LYG are attributed to the age of averted death,
not to the age at which the life years would have been
lived
Where do the gained years come from?
The treatment arm of the US IMPACT model estimates
patients’ median survival using population-based data
from unselected cohorts of MediCare patients following
their hospital admission for acute myocardial infarction,
heart failure, or revascularization. Additional age-specific
median survival data for unstable angina patients were
obtained from a large retrospective cohort study of
unselected patients in the United Kingdom [16-18],
since MediCare only included US patients aged over 65.
The risk factor arm of the model estimates survival
using the life expectancy of the general US population.
Favourable shifts in risk factors both prevent and post-
pone (clinical) onset of CHD. It is expected, therefore,
that some will live with asymptomatic CHD until their
first CHD event - which results in death. For this group
the post-AMI (excluding heart failure) rates are
employed (the maximum estimate is set at halfway
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Figure 2 IMPACT, schematic representation of transition probabilities reduced by favorable changes in risk factors and better
treatments*.
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between the life expectancy of post-AMI patients and
the general population and the minimum estimate is set
at the life expectancy of post-AMI patients including
those with heart failure). A portion of the CHD patients
will also be expected to have their deaths postponed
due to beneficial risk factor changes. This group is
assumed to have approximately the same life expectancy
as patients surviving after an uncomplicated AMI (Table
2). The main survival functions employed are illustrated
in Table 2.
How robust are the model extensions required for the
LYG metric?
The US IMPACT model uses five main data sources to
estimate survival and life expectancy (case-fatality rates
for post-AMI, heart failure, revascularization and
unstable angina patient groups and the general US life
expectancy) which are subsequently used to apply
weights to each CHD death prevented or postponed for
both the treatment and the risk factor arms of the
model. These weights are adjusted for different contexts
and for the specific groups of people who benefit from
clinical treatments or risk factor changes according to
informed assumptions (listed in Table 3).
For all healthy people who never experience a CHD
event, the model uses a universal weight, the general US
life expectancy (weight 1 in Figure 2). There are two
potential problems with this. First, the general US popu-
lation is made up of people who are both at risk of a
CHD death and those that are not at risk. The impact
of decreasing one’s exposure to a risk factor or risk fac-
tors, however, might be expected to improve one’s life
expectancy above that of the general population. The
assumption used here in the IMPACT model, therefore,
is likely to lead to conservative estimates of the gains
due to risk factor changes amongst the healthy
population.
Second, a universal life expectancy applied to deaths
averted amongst the ‘healthy’ populations due to risk
factors changes means that the specific benefits gained
from each risk factor change are lost. There are two rea-
sons why this one weight is employed however. First the
IMPACT model calculates the number of DPPs accord-
ing to specific risk profiles and the prevalence of each
risk factor. Any attempt to account for these differences
again would potentially double count the impact.
A separate but related issue arises from risk factors
being correlated [19] so the impact of changes in indivi-
dual risk factors is not additive. Thus, employing a com-
mon life expectancy for all those who avert a CHD
death due to risk factor changes avoids the methodolo-
gical problems that arise from non-additivity.
For the group of people with asymptomatic and/or
undiagnosed CHD, the model uses a weight that is mid-
way between the general US life expectancy and the sur-
vival rates of post-AMI patients (weight 2 in Figure 2).
Furthermore, people diagnosed with CHD may gain sur-
vival time either from better treatment or from favour-
able risk factor changes. This group are given a survival
weight equivalent to that of the post-AMI patient group
(weight 3 in Figure 2).
These assumptions suggest that these groups of people
have a small advantage in terms of survival and, again,
probably provide a conservative assessment of the
impact of risk factors on these groups of people.
Lastly, patient group specific survival rates are used to
weight the death prevented or postponed from a treat-
ment (weight 4 in Figure 2). Weight 4 is based on case
Table 1 Results of pairs of studies using the IMPACT model: for each of 4 countries one study was performed using
Deaths Prevented or Postponed (DPPs) and one using Life Years Gained (LYG).
DPPs (% share) LYG (% share) LYG per DPP
USA 1980-2000 [4,11]
Better treatment 159,300 (52%) 1,092,300 (35%) 6.9
Favourable risk factor changes 149,600 (48%) 2,055,600 (65%) 13.7
Ireland 1985-2000 [3,10]
Better treatment 1640 (47.5%) 14,505 (31%) 8.8
Favourable risk factor changes 1810 (52.5%) 32,705 (69%) 18
England and Wales 1981-2000 [2,8]
Better treatment 25,765 (42%) 194,145 (21%) 7.5
Favourable risk factor changes 35,830 (58%) 731,270 (79%) 20.4
Scotland 1975-1994 [1,9]
Better treatment 1862 (41%) 12025 (25%) 6.5
Favourable risk factor changes 2674 (59%) 35991 (75%) 13.5
Data are the population totals for DPP and LYG (% share) and the ratios of LYG to DPP
DPP = Deaths Prevented or Postponed LYG = Life Years Gained
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fatality data for most of the patient groups included in
the model. Two main groups, however, community
heart failure and hypertension, lack sufficient data to
inform on survival. To estimate survival for these two
groups the model uses the assumptions that those
experiencing heart failure in the community have one
third of the case fatality of those who suffer heart failure
in the hospital and those with hypertension will have
20% less life expectancy than the average life expectancy.
Little literature exists to inform these estimates and
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Figure 3 IMPACT results for US men in 2000 relative to 1980: Deaths prevented or postponed (DPP) and life years gained (LYG) attributed
to better treatment and to risk factor changes by age (for DPP) and age of averted onset (LYG)*.
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these assumptions may slightly overestimate the number
of years lost due to these conditions [20].
To answer the question posed above, therefore, all
groups of people that may have avoided or postponed a
CHD death have been accounted for in the US IMPACT
model and the assumptions used to extend this analysis
from the event-based metric DPP to the time-based
metric LYG may at times seem speculative and even
Table 2 Life expectancies (ex) assigned to US men and women in 2000, comparing those who have not progressed to
clinical CHD (’healthy’) with those who have survived an acute myocardial infarction without the onset of heart failure
and those who progress to heart failure
Age (x) Life expectancy at exact age (ex)
Healthy
population1
Those who have survived an AMI by 30 days (excluding
those with HF*)2
Those who have survived an AMI by 30 days but
remain in HF* 3
MALES
30 45.9 28.0 14.8
40 36.7 28.0 7.4
50 27.9 14.6 5.2
60 19.9 9.7 3.6
70 13.0 6.8 1.8
80 7.6 4.1 1.5
90 4.1 2.6 1.2
100+ 2.4
FEMALES
30 50.6 28.0 14.8
40 41.0 28.0 7.4
50 31.8 14.6 5.2
60 23.1 9.7 3.6
70 15.5 6.8 1.8
80 9.1 4.1 1.5
90 4.8 2.6 1.2
100+ 2.7
* Heart failure
1 Source: US Government Actuary’s Office [17]
2 Source: Based upon median survival estimated from case fatality data obtained from MediCare [4]
3 Source: Based upon median survival estimated from case fatality data obtained from [4]
Table 3 Survival functions assigned to specified health states: sources, limitations and strengths
Data used Data
source
Limitations of assumption Strengths of assumption
Treatments CHD patients. Heart failure (HF) in the
community is assumed to result in one
third the fatality as HF in hospital and
hypertension life expectancy is 80% that
of US general population
MediCare [4] May overestimate the life years lost
due to deaths caused by HF in the
community and hypertension.
May overestimate the impact of
treatments preventing and postponing
deaths due to HF in the community
and hypertension therefore making
the estimated relative contribution of
risk factors conservative.
Risk
Factors
CHD patients. Median survival was
assumed to be that of the post-AMI
patients
MediCare [4] May underestimate the benefit of
reductions in risk factor prevalence
Provides a conservative estimate
Healthy population. survival was
assumed to be that of general US
population
US Bureau
of the
Census [17]
May both underestimate and
overestimate the benefit or harms in
terms of survival for each of the
changes in risk factor prevalence
Avoids methodological issues of non-
additivity and double-counting
Asymptomatic CHD. Survival was
estimated as half-way between that of
post-AMI patient and General US life
expectancy
MediCare
and US
Bureau of
the Census
[4,17]
Arbitrary and may underestimate the
benefit of reductions in risk factor
prevalence
Provides a conservative estimate
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arbitrary, but the estimates are typically reasonable and
often conservative. In other words, the model is likely to
underestimate gains in life years from favourable
changes in risk factors.
Discussion
Changes in disease determinants gain policy relevance
from their effects on the population’s burden of disease.
This applies to both risk factor changes and to thera-
pies. We have shown how these effects are better cap-
tured when expressed in a time-based metric such as
life years gained (LYG).
Extending the IMPACT model to enable outputs in
LYG required additional assumptions but these turned
out to be relatively robust and unlikely to seriously off-
set the wider advantages of the LYG model.
Although results from analyses based in LYG differ
importantly in their policy implications from analyses
based in DPP, it is striking that there has been little dis-
cussion of the respective merits of public health models
employing these two alternative metrics. Given that
public health modelling influences public health policy,
it is important to ‘get it right’. Criteria are therefore
needed for the critical appraisal of such models. From
our demonstration that choice of metric can be highly
consequential in such models it follows that reports of
modelling exercises should explicitly justify their choice
of metric.
Time-based metrics will usually be better because:
a They direct attention to changes in the natural his-
tory of the disease produced by the change in health
determinants This aids understanding of ‘what is going
on’ in the population’s health experience;
b Life years gained relate more closely to the social
value of the changes in population health. Deaths, con-
sidered as instantaneous events, are weightless. It is the
life foregone that matters.
Some limitations of this investigation should be noted.
Furthermore, the many assumptions and limitations of
the US IMPACT model have previously been noted
[4,11]. In this review of the IMPACT model we have
therefore focussed mainly on the assumptions involved
in estimating LYG due to CHD treatments and risk fac-
tor changes, and not on those involved in estimating the
underlying deaths postponed or prevented (DPPs).
Clearly, as the life years gained are calculated as weights
for each DPP, assumptions which weaken the DPP
model will, therefore, impact upon the results of the
LYG model as well. However, it was not our purpose to
evaluate the specific results of either model but rather
to assess the use of time-based outcome (LYG) versus
an event-based outcome (DPP). Another limitation of
our study is that we have not quantified the uncertainty
around each assumption in this paper and this may be
warranted in future efforts in order to identify where to
focus further detailed work and clarifications.
Lastly, here we have considered just two metrics for
capturing changes in disease occurrence. Our argument
generalises to choice from among the full spectrum of
available metrics - from the purely objective metrics of
aetiologic epidemiology, to metrics based in objective
phenomena but weighted to take account of social
values (such as life years lost and gained), to hybrid
measures such as the DALY which entail some formal
valuing of health states but which maintain strong links
to the ‘objectivist’ categories of medical science, to
metrics located within the subjectivist theory of value of
economics (’extra-welfarist’ QALYs and ‘welfarist’
QALYs [21]). Methodological pluralism can enrich pub-
lic health. No one metric meets all purposes, so choices
from among them should be deliberate and justified.
Conclusion
In conclusion, time-based metrics (such as life years) are
generally preferable to simply enumerating deaths pre-
vented, because life years direct attention to the changes
in the natural history of disease that are produced by
changes in key health determinants. The life-years
metric also better reflects social preferences.
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